SGP Stock Forecast & Price Target

SpyGlass Pharma is attractive because its four-year first-in-human BIM-IOL data showed a 37% mean intraocular pressure reduction from 25.1 mmHg to 15.9 mmHg, with 86% of 21 evaluable patients remaining off topical drops and no product-related adverse events, supporting the durability of its sustained-release platform. The results also preserved vision, with 90% of patients maintaining 20/25 or better best corrected distance visual acuity, which reinforces the clinical value proposition for glaucoma patients undergoing cataract surgery. Fundamentally, the approximately $13M acquisition of Advanced Vision Science strengthens long-term supply security for intraocular lenses and should help accelerate premium IOL innovation, improving the company’s commercialization readiness.

SpyGlass Pharma is viewed negatively because its valuation rests heavily on a single asset, with $1,025M of DCF-based value tied to the BIM-IOL System and only $221M of pro forma cash supporting the story. The investment case also depends on a modest 55% probability of U.S. approval, leaving substantial regulatory risk alongside the possibility of clinical failure, commercialization shortfalls, and dilution. Even with 33.5M shares outstanding at the end of 2Q27, the firm remains vulnerable to execution risk because its pipeline is narrow and its outcome is highly binary.